Browsing Tag
Rachel Parsonage
1 post
SkinBioTherapeutics (LSE: SBTX) is growing again, but will cash last long enough?
SkinBioTherapeutics is growing revenue, but cash and credibility remain tight. New FY2026 guidance will decide whether SBTX can rerate.